Discovery of SARS-CoV-2 PLpro covalent inhibitors enabled by a novel reversible covalent chloroalkyne warhead.
These findings establish chloroalkyne as a promising target-directed reversible covalent warhead for PLpro inhibition and provide in vivo proof-of-concept for this chemistry in antiviral drug discovery, with potential for broader application to other cysteine proteases.